Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

BACKGROUND: Ponatinib has shown efficacy in patients with refractory chronic myeloid leukaemia (CML) and in those with CML with a Thr315Ile mutation. We aimed to investigate the activity and safety of ponatinib as first-line treatment for patients with chronic-phase CML. METHODS: We did a single-arm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Haematol
Autors principals: Jain, Preetesh, Kantarjian, Hagop, Jabbour, Elias, Gonzalez, Graciela Nogueras, Borthakur, Gautam, Pemmaraju, Naveen, Daver, Naval, Gachimova, Evguenia, Ferrajoli, Alessandra, Kornblau, Steven, Ravandi, Farhad, O’Brien, Susan, Cortes, Jorge
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4587395/
https://ncbi.nlm.nih.gov/pubmed/26436130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(15)00127-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars